Shire PLC (SHPG) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Shire PLC (NASDAQ: SHPG) in the last few weeks:

  • 7/26/2017 – Shire PLC was given a new $159.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 7/19/2017 – Shire PLC was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/17/2017 – Shire PLC had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $242.00 price target on the stock.
  • 7/17/2017 – Shire PLC was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 22% of the total market by the end of Mar 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Earnings estimates have fallen lately ahead of the Q2 results. Shire has a positive record of earnings surprises in the recent quarters.”
  • 7/13/2017 – Shire PLC had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $210.00 price target on the stock.
  • 7/12/2017 – Shire PLC had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $245.00 price target on the stock.
  • 7/11/2017 – Shire PLC was given a new $222.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/6/2017 – Shire PLC was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 7/6/2017 – Shire PLC was upgraded by analysts at HSBC Holdings plc from a “reduce” rating to a “hold” rating.
  • 7/1/2017 – Shire PLC was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/1/2017 – Shire PLC was given a new $222.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 6/23/2017 – Shire PLC was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 6/16/2017 – Shire PLC was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 6/16/2017 – Shire PLC is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $222.00 price target on the stock.
  • 6/9/2017 – Shire PLC was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 6/9/2017 – Shire PLC had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $216.00 price target on the stock, down previously from $239.00.
  • 6/9/2017 – Shire PLC had its price target lowered by analysts at Stifel Nicolaus from $250.00 to $245.00. They now have a “buy” rating on the stock.
  • 6/8/2017 – Shire PLC was given a new $218.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 6/2/2017 – Shire PLC was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 6/1/2017 – Shire PLC was downgraded by analysts at Liberum Capital from a “buy” rating to a “hold” rating.

Shares of Shire PLC (NASDAQ SHPG) opened at 168.29 on Monday. Shire PLC has a one year low of $158.54 and a one year high of $209.22.

Shire PLC (NASDAQ:SHPG) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 EPS for the quarter, topping the Zacks’ consensus estimate of $3.22 by $0.41. The business had revenue of $3.57 billion for the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. Shire PLC’s revenue was up 109.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.12 earnings per share. On average, analysts expect that Shire PLC will post $14.78 EPS for the current year.

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply